Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
32,363,756
-
Share change
-
+1,816,433
-
Total reported value
-
$522,852,140
-
Price per share
-
$16.15
-
Number of holders
-
60
-
Value change
-
+$27,797,027
-
Number of buys
-
33
-
Number of sells
-
19
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q1 2022
As of 31 Mar 2022,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,363,756 shares.
The largest 10 holders included
Cormorant Asset Management, LP, BlackRock Inc., Logos Global Management LP, CITADEL ADVISORS LLC, EcoR1 Capital, LLC, Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, and JANUS HENDERSON GROUP PLC.
This page lists
60
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.